Shein’s U.S. buyout hits a political wall, as China’s fintech lenders face ruin
“There’s been a very definite trend of what I would call re-transferring part of the economy from the private sector to the state sector.” — on Beijing’s regulatory retreat from…
How China’s trade surplus is floating Hong Kong equities, even as Western bulls retreat
"The one thing that professional investors or sophisticated investors fear the most is uncertainty." Rene Vanguestaine
China’s AI regulation debate enters the agent era
As AI shifts from generating content to taking action, it is no longer just a technology story — but a governance challenge By Vivian Toh China’s annual “Two Sessions”…
Regulatory caution dims Hong Kong SPAC outlook, while Chinese tastes drive out foreign brands
Hong Kong has completed just its third listing using a SPAC since the program's launch four years ago. Why has uptake been so anemic? And Hong Kong's popular Mannings health and beauty chain is pulling out of Mainland China after more than two decades in the market. Why is it calling it quits?
Nasdaq gets tough on small Chinese IPOs, as an AI-fueled energy storage boom takes off
For a market that basically prides itself on protecting investors… I have to say I'm amazed that it has taken so long.
Hong Kong: China’s IPO pipeline and crypto lab
Companies raised $13.6 billion through Hong Kong IPOs in the first half of the year, giving the city the global fundraising title for that period. What's behind the sudden boom? And a growing number of Chinese companies are experimenting with cryptocurrencies in Hong Kong, even as such currencies are banned on the Mainland. What's driving such different approaches on the Mainland and in Hong Kong?
PODCAST: A Bubble Tea IPO Freeze, and a Revenue-less Drug Maker
China's securities regulator puts the brakes on new bubble tea IPOs in Hong Kong. Is this China's latest step to assert its authority over the former British colony? And former drug making highflyer Ascletis has become revenue-less after its earlier drugs fizzled. Now the company is hoping to revive its fortunes with a new weight-loss drug from the same class as Ozempic.
Recent Articles
RELATED ARTICLES
-
Shifting identities: Shein’s acquisition and Canadian Solar’s return to North America
- BRIEF: Shein to acquire U.S. peer Everlane for $100 million
- For Futu and UP Fintech, regulatory bombshell may finally clear global path forward
- Declawed in China, UP Fintech faces challenges in global marketplace
-
Yiren, Qfin swept up in latest fintech lending crackdown
YRD.US3660.HKQFIN.US
- China’s changing consumer economy: A fintech lending crackdown and a toothpaste IPO
- Shein pushes for higher valuation ahead of Hong Kong IPO launch
